Comparative pharmacokinetics of two modified-release oral morphine formulations (Reliadol® and Kapanol®) and an immediate-release morphine tablet (Morfin 'DAK') in healthy volunteers

Clinical Drug Investigation

Volumn 17, Issue 1, 1999, Pages 59-66

  Bochner, F ^a   Somogyi, A A ^a   Christrup, L L ^b   Larsen, U ^c   Danz, C ^a   Elbaek K ^c  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c Nycomed Denmark   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

MORFIN DAK; MORPHINE; MORPHINE SULFATE; RELIADOL; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; MEAN RESIDENCE TIME; NAUSEA; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0032926419     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-199917010-00007     Document Type: Article

References (21)

1. Schug SA, Zech D, Grond S, et al. A long term survey of morphine in cancer pain patients. J Pain Symptom Manage 1992; 7: 259-66
2. Gourlay GK, Cherry DA, Onley MM, et al. Pharmacokinetics and pharmacodynamics of twenty-four-hourly Kapanol compared to twelve-hourly MS Contin in the treatment of severe cancer pain. Pain 1997; 69: 295-302
3. Hanks GW, Hanna M, Finlay I, et al. Efficacy and pharmacokinetics of a new controlled-release morphine sulfate 200-mg tablet. J Pain Symptom Manage 1995; 10: 6-12
4. Forman WB, Portenoy RK, Yanagihara RH, et al. A novel morphine sulphate preparation: clinical trial of a controlled-release morphine suspension in cancer pain. Pall Med 1993; 7: 301-6
5. Faura CC, Moore RA, Horga JF, et al. Morphine and morphine-6-glucuronide plasma concentrations and effect in cancer pain. J Pain Symptom Manage 1996; 11: 95-102
6. Milne RW, Nation RI, Sornogyi AA. The disposition of morphine and its 3- and 6-glucuronide metabolites in humans and animals, and the importance of the metabolites to the pharmacological effects of morphine. Drug Metab Rev 1996; 28: 345-472
7. Tyrefors N, Hyllbrant B, Ekman L, et al. Determination of morphine-3-glucuronide and morphine-6-glucuronide in human serum by solid-phase extraction and liquid chromatographymass spectrometry with electrospray ionisation. J Chromatogr 1996; 729: 279-85
8. Gourlay GK, Plummer JL, Cherry DA, et al. A comparison of Kapanol (a new sustained-release morphine formulation), MST Continus, and morphine solution in cancer patients: pharmacokinetic aspects of morphine and morphine metabolites. Proceedings of the 7th World Congress on Pain. In: Gebhardt GF, Hammond DL, Jensen TS, editors. Progress in Pain Research and Management. Seattle: IASP Press, 1994; 2: 631-43
9. Thirlwell MP, Sloan PA, Maroun JA, et al. Pharmacokinetics and clinical efficacy of oral morphine solution and controlled-release morphine tablets in cancer patients. Cancer 1989; 63: 2275-83
10. Smith KJ, Miller AJ, McKellar J, et al. Morphine at gramme doses: kinetics, dynamics and clinical need. Postgrad Med J 1991; 67: S55-S59
11. Hasselström J, Alexander N, Bringel C, et al. Single-dose and steady-state kinetics of morphine and its metabolites in cancer patients - a comparison of two oral formulations. Eur J Clin Pharmacol 1991; 40: 585-91
12. Broomhead A, West R, Eglinton L, et al. Comparative single-dose pharmacokinetics of sustained-release morphine sulfate capsules under fed and fasting conditions. Clin Drug Invest 1997; 13: 162-70
13. Maccarrone C, West RJ, Broomhead AF, et al. Single dose pharmacokinetics of Kapanol™, a new oral sustained-release morphine formulation. Drug Invest 1994; 7: 262-74
14. Bashaw ED, Kaiko RF, Grandy RP, et al. Relative bioavail-ability of controlled-release oral morphine sulfate during naltrexone blockade. Int J Clin Pharmacol Ther 1995; 33: 524-9
15. Drake J, Kirkpatrick CT, Aliyar CA. Effect of food on the comparative pharmacokinetics of modified-release morphine tablet formulations: Oramorph SR* and MST Continus. Br J Clin Pharmacol 1996; 41: 417-20
16. Vater M, Smith G, Aherne GW, et al. Pharmacokinetics and analgesic effect of slow-release oral morphine sulphate in volunteers, Br J Anaesth 1984; 56: 821-7
17. Hunt TL, Kaiko RF. Comparison of the pharmacokinetic profiles of two oral controlled-release morphine formulations in healthy young adults. Clin Ther 1991; 13: 482-48
18. Savarese JJ, Goldenheim PD, Thomas GB, et al. Steady-state pharmacokinetics of controlled release oral morphine sulphate in healthy subjects. Clin Pharmacokinet 1986; 11: 505-10
19. Kaiko RF, Grandy RP, Reder RF, et al. A bioequivalence study of oral controlled-release morphine using naltrexone blockade. J Clin Pharmacol 1995; 35: 499-504
20. Bass J, Shepard KV, Lee JW, et al. An evaluation of the effect of food on the oral bioavailability of sustained-release morphine sulfate tablets (ORAMORPH SR) after multiple doses. J Clin Pharmacol 1992; 32: 1003-7
21. Westerling D, Frigren L, Höglund P. Morphine pharmacokinetics and effects on salivation and continuous reaction times in healthy volunteers. Ther Drug Monit 1993, 15: 364-74